- The partnership focuses on antibiotic-free plasmid DNA manufacturing.
- WACKER's ESETEC platform and Gearbox's Pop-Out-Plasmid technology are central to the collaboration.
- Initial milestones include evaluating Pop-Out-Plasmid technology within the PLASMITEC toolbox.
- The project is supported by WACKER's Biotechnology Center in Munich.
Collaboration Overview
WACKER and Gearbox Biosciences have announced a strategic partnership to advance plasmid DNA (pDNA) manufacturing technologies. The collaboration aims to address current challenges in scalability, efficiency, and cost-effectiveness of pDNA production, which is crucial for developing advanced therapies.
Technological Focus
The partnership will leverage WACKER's expertise in GMP manufacturing and Gearbox's innovative solutions for antibiotic-free plasmid proliferation. A key focus is on developing workflows for antibiotic-free pDNA manufacturing and tackling difficult-to-manufacture sequences. This approach promises improved scalability and sustainability compared to existing methods.
Key Technologies
Central to the collaboration are WACKER's ESETEC platform and Gearbox's Pop-Out-Plasmid technology. These technologies aim to eliminate antibiotics from the production process, reducing the risk of spreading antibiotic resistance. The joint effort will integrate these technologies into WACKER's PLASMITEC toolbox.
Project Milestones
The collaboration is already underway, with initial milestones including the evaluation of Gearbox's Pop-Out-Plasmid technology within the PLASMITEC toolbox. The project is supported by the recently opened WACKER Biotechnology Center in Munich, which provides optimal conditions for advancing these technologies.
